Nutrition and Cancer · 2010 · 279 citations · 26 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyOncology PharmacotherapyPancreatic CancerToxicity ManagementAntiproliferative AgentsAntiproliferative Drug ActionComparative Effectiveness Of FormulationsComplianceGemcitabine-based TherapyPancreatic Cancer PharmacotherapyPancreatic Cancer Systemic TherapyPartial Response Assessment
Curcumin has a potent antiproliferative activity and can also potentiate the antitumor effect of gemcitabine. This study was undertaken to evaluate the activity and feasibility of gemcitabine in combination with curcumin in patients with advanced pancreatic cancer. Seventeen patients were enrolled in the study and received 8,000 mg of curcumin by mouth daily, concurrently with gemcitabine 1,000 mg/m(2) IV weekly × 3 of 4 wk; 5 patients (29%) discontinued curcumin after a few days to 2 wk due to intractable abdominal fullness or pain, and the dose of curcumin was reduced to 4,000 mg/day because of abdominal complaints in 2 other patients. One of 11 evaluable patients (9%) had partial response, 4 (36%) had stable disease, and 6 (55%) had tumor progression. Time to tumor progression was 1-12 mo (median 2½), and overall survival was 1-24 mo (median 5). Low compliance for curcumin at a dose of 8,000 mg/day, when taken together with systemic gemcitabine, may prevent the use of high doses of oral curcumin needed to achieve systemic effect. Further studies should be conducted to evaluate the ability of other formulations of curcumin to enhance the effect of chemotherapy in cancer patients.
26
Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.9K citations
Medicine, Oncology, Pharmacotherapy +16
Malcolm J. Moore, David Goldstein, John Hamm et al. · Journal of Clinical Oncology · 2007 · 3.9K citations
Medicine, Oncology, Pharmacology +17
Anticancer potential of curcumin: preclinical and clinical studies.
Bharat B. Aggarwal, Anushree Kumar, Alok C. Bharti · PubMed · 2003 · 2.6K citations
Medicine, Oncology, Pharmacology +15
Ann‐Lii Cheng, Chih‐Hung Hsu, Jen‐Kou Lin et al. · PubMed · 2001 · 2.1K citations
Medicine, Oncology, Pharmacology +10